Not Signed In -
Hemochromatosis, type 3 |
idiopathic hemochromatosis |
Clinical Trial: Efficacy and Safety of Vildagliptin in Patients with Type 2 Diabetes
This study is currently recruiting patients.
|
Purpose
This study is not being conducted in the United States. The purpose is to determine the safety and effectiveness of vildagliptin, an unapproved drug, compared to a marketed drug for type 2 diabetes.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 | Drug: vildagliptin | Phase III |
MedlinePlus related topics: Diabetes
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Primary Outcomes: Blood glucose levels
Study start: January 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
- Pregnancy or lactation
- Type 1 diabetes
- Evidence of significant diabetic complications
Location and Contact Information
Switzerland
Novartis Pharmaceuticals, Basel, Switzerland; Recruiting
Customer Information Center 862-778-8300
More Information
Novartis patient recruitment website
Study ID Numbers: CLAF237A2310
Record last reviewed: January 2005
Last Updated: January 28, 2005
Record first received: January 28, 2005
ClinicalTrials.gov Identifier: NCT00102388
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: January 2005
Last Updated: January 28, 2005
Record first received: January 28, 2005
ClinicalTrials.gov Identifier: NCT00102388
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Hemochromatosis, type 3 (Genetics Home Reference)
email this page
print this page
bookmark this page
feedback on this page
